Our Pricing

Understanding Wegovy Levels - Complete UK Dosing Schedule Guide

Published: 11 September 2026

Wegovy levels refer to the carefully structured dose escalation schedule that gradually increases semaglutide from an initial 0.25mg weekly dose to a maintenance level of 2.4mg over 16-20 weeks. This titration approach, validated in the STEP clinical trial programme, minimises gastrointestinal side effects whilst allowing your body to adapt to the GLP-1 receptor agonist mechanism. At Cured Pharmacy, our UK-registered clinical team provides comprehensive guidance on navigating each Wegovy level safely, with transparent pricing from £69.00 and ongoing prescriber support throughout your dose escalation journey.

What Are Wegovy Levels and Why Does Dosing Escalate?

Wegovy levels describe the five distinct dosing stages used in semaglutide treatment for weight management, starting at 0.25mg weekly and progressing through 0.5mg, 1mg, 1.7mg, and finally reaching the therapeutic maintenance dose of 2.4mg per week[1]. This graduated approach is not arbitrary—clinical evidence from the STEP trials demonstrated that gradual dose escalation significantly reduces the incidence and severity of gastrointestinal adverse events compared to starting at higher doses immediately.

Each Wegovy level serves a specific physiological purpose. The initial 0.25mg and 0.5mg doses prime your GLP-1 receptors without overwhelming your digestive system, allowing gastric emptying to slow gradually whilst appetite suppression begins[2]. As you progress through higher Wegovy levels, the metabolic effects intensify—insulin sensitivity improves, hepatic glucose output decreases, and satiety signals strengthen. The 2.4mg maintenance level represents the dose at which clinical trials observed maximum weight reduction, with participants losing an average of 14.9% body weight over 68 weeks[1].

Understanding Wegovy levels is crucial for setting realistic expectations. Many patients notice modest appetite changes at the 0.25mg starting level, but significant weight loss typically accelerates once reaching the 1mg to 1.7mg range. Our superintendent pharmacist Tarun Kumar emphasises that rushing through Wegovy levels or skipping doses increases discontinuation rates due to nausea and vomiting—patience with the titration schedule yields better long-term adherence and outcomes.

The Complete Wegovy Levels Titration Schedule for UK Patients

The standard Wegovy levels progression follows a 20-week escalation protocol approved by the MHRA for UK use. You begin with 0.25mg once weekly for four weeks (Month 1), then increase to 0.5mg weekly for the next four weeks (Month 2)[3]. Month 3 involves the 1mg weekly dose, followed by 1.7mg weekly during Month 4. From Month 5 onwards, you maintain the 2.4mg weekly therapeutic dose unless tolerability issues require adjustment.

This Wegovy levels schedule can be modified based on individual tolerance. If you experience persistent nausea, vomiting, or diarrhoea at any level, your prescriber may recommend staying at your current dose for an additional 2-4 weeks before escalating[3]. Conversely, the schedule should never be accelerated—jumping Wegovy levels or increasing doses more quickly than recommended significantly raises the risk of treatment-limiting side effects without improving weight loss efficacy.

At Cured Pharmacy, our UK-registered prescribers assess your tolerance at each Wegovy level through follow-up consultations included in your treatment plan. We supply Wegovy pens pre-filled with the exact dose for your current level, eliminating dosing errors. The 0.25mg and 0.5mg starter pens contain four doses each, whilst the 1mg, 1.7mg, and 2.4mg maintenance pens also provide four weekly injections per pen. This packaging structure ensures you complete each Wegovy level fully before progressing.

Adjusting Wegovy Levels for Side Effect Management

Approximately 44% of patients in the STEP 1 trial reported gastrointestinal adverse events, most commonly during the early Wegovy levels[1]. If side effects become problematic at any dose, clinical guidance supports remaining at your current level for an extended period rather than discontinuing treatment entirely. Some patients require 6-8 weeks at the 1mg or 1.7mg Wegovy levels before tolerating escalation to 2.4mg.

If you miss doses and the gap exceeds two weeks, you may need to restart at a lower Wegovy level to re-establish tolerance—your prescriber will determine the appropriate re-initiation dose based on how long treatment was interrupted[3]. This flexible approach to Wegovy levels management helps maximise treatment completion rates whilst maintaining safety.

How Wegovy Levels Affect Weight Loss Outcomes and Timelines

Weight loss velocity varies significantly across Wegovy levels. During the initial 0.25mg and 0.5mg doses (Months 1-2), patients typically lose 2-4% of baseline body weight—primarily through appetite reduction and decreased caloric intake[2]. The most rapid weight loss phase occurs between the 1mg and 1.7mg Wegovy levels (Months 3-4), when patients often experience 1-2kg reductions per week as metabolic effects fully engage.

The 2.4mg maintenance Wegovy level sustains ongoing weight reduction, though the rate gradually slows. STEP trial data showed that participants reaching the 2.4mg dose by Month 5 continued losing weight until approximately Week 60, after which weight stabilised[1]. The average total weight loss at 68 weeks was 14.9% of initial body weight for those completing the full Wegovy levels protocol, compared to 2.4% in the placebo group.

It is essential to understand that Wegovy levels work synergistically with lifestyle modifications. Patients who combine the medication with structured dietary changes and increased physical activity at each dose level achieve superior outcomes compared to those relying on pharmacotherapy alone[2]. Our clinical team at Cured Pharmacy provides evidence-based lifestyle guidance tailored to your current Wegovy level, optimising results throughout your treatment journey.

Plateau Effects at Higher Wegovy Levels

Some patients experience weight loss plateaus after several months at the 2.4mg maintenance Wegovy level. This phenomenon reflects metabolic adaptation rather than medication failure. Research indicates that continuing treatment at the therapeutic dose prevents weight regain even during plateau phases, with discontinuation typically resulting in regaining two-thirds of lost weight within one year[1].

If weight loss stalls at the maintenance Wegovy level despite adherence, your prescriber may investigate secondary factors such as medication interactions, underlying endocrine conditions, or dietary patterns that could be limiting further progress. Adjusting Wegovy levels downward is rarely beneficial for plateau management—maintaining the 2.4mg dose whilst addressing lifestyle factors yields better long-term outcomes.

Wegovy Levels Compared to Other GLP-1 Dose Schedules in the UK

Wegovy levels follow a more gradual escalation than some other GLP-1 receptor agonists available in the UK. Saxenda (liraglutide), for instance, increases by 0.6mg daily increments over five days, reaching the 3mg maintenance dose within one week—a much faster titration that contributes to higher early discontinuation rates[4]. Wegovy's extended 20-week progression through five distinct levels allows superior gastrointestinal adaptation.

Mounjaro (tirzepatide) employs a similar graduated approach to Wegovy levels, starting at 2.5mg weekly and escalating every four weeks through 5mg, 7.5mg, 10mg, and optionally 12.5mg or 15mg maintenance doses[5]. Whilst both medications use monthly dose increases, tirzepatide's starting dose is ten times higher than Wegovy's initial 0.25mg level, reflecting differences in receptor binding profiles and tolerability characteristics between the two compounds.

The Wegovy levels system represents current best practice for semaglutide dosing in weight management. Ozempic, which contains the same active ingredient but is licensed for type 2 diabetes rather than obesity, uses a different escalation schedule (0.25mg to 0.5mg to 1mg, with optional 2mg maximum) that does not include the 1.7mg intermediate step or the 2.4mg therapeutic dose validated for weight loss[3]. Patients prescribed Wegovy specifically benefit from the evidence-based dose levels optimised for body weight reduction rather than glycaemic control.

Managing Side Effects Across Different Wegovy Levels

Side effect profiles change as you progress through Wegovy levels. Nausea is most common during the first two dose escalations (0.25mg to 0.5mg and 0.5mg to 1mg transitions), affecting approximately 20% of patients at these stages[1]. The intensity typically peaks 2-3 days after your first injection at a new Wegovy level, then diminishes over the subsequent week as tolerance develops.

Gastrointestinal symptoms at any Wegovy level can be minimised through evidence-based strategies. Eating smaller, more frequent meals rather than three large portions reduces gastric distension when emptying is slowed. Avoiding high-fat foods, which delay gastric emptying further, decreases nausea severity at all dose levels[2]. Adequate hydration (2-3 litres daily) prevents constipation, which becomes more prevalent at the higher 1.7mg and 2.4mg Wegovy levels.

Serious adverse events are rare but require immediate medical attention regardless of your current Wegovy level. Severe abdominal pain, especially if radiating to the back, may indicate pancreatitis—a condition reported in 0.2% of semaglutide users[3]. Persistent vomiting preventing fluid intake, symptoms of gallbladder disease, or signs of thyroid nodules warrant urgent prescriber review. At Cured Pharmacy, our clinical team remains accessible throughout your progression through Wegovy levels, providing same-day guidance for any concerning symptoms.

Injection Site Reactions at All Wegovy Levels

Injection site reactions—redness, swelling, or itching—can occur at any Wegovy level but are generally mild and transient. Rotating injection sites between abdomen, thigh, and upper arm with each weekly dose reduces localised irritation. If site reactions worsen or persist beyond 48 hours at your current dose level, consult your prescriber to rule out rare hypersensitivity reactions requiring treatment modification.

Accessing Wegovy Levels Through Cured Pharmacy - Pricing and Clinical Support

Cured Pharmacy supplies all Wegovy levels with full UK prescriber oversight from £69.00 per month, representing the most competitive pricing available from a GPhC-registered online pharmacy. This transparent cost structure covers your medication supply, clinical assessment, prescriber consultations, and delivery—with no hidden fees as you progress through dose levels. New patients receive £20 off their first order using code Weightlossnew, reducing initial treatment costs whilst you establish tolerance at the starting Wegovy level.

Our streamlined process begins with a comprehensive online assessment reviewed by UK-registered prescribers, typically completed in under three minutes. Once approved, we dispense the appropriate Wegovy level for your current stage in the titration schedule, with automatic reminders when you are due to escalate. Follow-up consultations at each dose transition ensure your progression through Wegovy levels remains safe and effective, with prescribers available to address side effects or adjust timing as needed.

All Wegovy levels supplied by Cured Pharmacy are genuine Novo Nordisk products sourced through licensed UK wholesalers—never grey market imports or compounded alternatives. Each pen arrives in discreet packaging with full patient information leaflets and injection guidance specific to your current dose. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees dispensing quality, ensuring you receive the correct Wegovy level every time. With same-day prescriber responses and next-day delivery across the UK, Cured Pharmacy provides the clinical support and convenience essential for successfully completing the full Wegovy levels protocol.

Long-Term Treatment Planning Across Wegovy Levels

Weight management with Wegovy typically requires 12-18 months of treatment to achieve and consolidate maximum weight loss, meaning you will spend most of this period at the 2.4mg maintenance level after completing the initial escalation. Cured Pharmacy offers flexible subscription options that reduce per-dose costs for patients committed to long-term treatment, with the ability to pause or adjust your supply if you need to remain at a particular Wegovy level longer than the standard schedule.

NICE guidance recommends continuing Wegovy only if you achieve at least 5% weight loss after 6 months of treatment—typically by the time you have been at the 2.4mg maintenance level for 8-12 weeks[6]. Our prescribers monitor your progress at each Wegovy level, ensuring you meet clinical criteria for ongoing therapy whilst optimising your dose schedule for both efficacy and tolerability.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 11 September 2026]
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 11 September 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 11 September 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 11 September 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 11 September 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. [accessed 11 September 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.